

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 10

### Complete if Known

Application Number	09/779,086
Filing Date	February 7, 2001
First Named Inventor	Chinery, R., et al.
Group Art Unit	1639
Examiner Name	Bennett Celsa
Attorney Docket Number	04676.105058 ATH 108 CON 1

3273118 5

### U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
K	AA	3,479,407		LAUFER	11-18-1969	
	AB	3,576,883		NEUWORTH	04-27-1971	
	AC	4,029,812		WAGNER, et al.	06-14-1977	
	AD	4,076,841		WAGNER, et al.	02-28-1978	
	AE	4,078,084		WAGNER, et al.	03-07-1978	
	AF	4,752,616		HALL, et al.	06-21-1988	
	AG	4,954,514		KITA, et al.	09-04-1990	
	AH	5,035,878		BORCH, et al.	07-30-1991	
	AI	5,155,250		PARKER, et al.	10-13-1992	
	AJ	5,206,247		REGNIER, et al.	04-27-1993	
	AK	5,215,892		KISHIMOTO, et al.	06-01-1993	
	AL	5,262,409		MARGOLIS, et al.	11-16-1993	
	AM	5,262,439		PARTHASARATHY	11-16-1993	
	AN	5,294,430		BORCH, et al.	03-15-1994	
	AO	5,348,963		GANDY, et al.	09-20-1994	
	AP	5,360,894		KISHIMOTO, et al.	11-01-1994	
	AQ	5,380,747		MEDFORD, et al.	01-10-1995	
	AR	5,545,563		DARLINGTON, et al.	08-13-1996	
	AS	5,608,095		PARKER, et al.	03-04-1997	
	AT	5,627,205		REGNIER, et al.	05-06-1997	
M	AU	5,674,492		ARMITAGE, et al.	10-07-1997	
	AV	5,750,351		MEDFORD, et al.	05-12-1998	
	AW	5,773,209		MEDFORD, et al.	06-30-1998	
	AX	5,773,231		MEDFORD, et al.	06-30-1998	

Examiner  
Signature


Date  
Considered

5/15/06


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → 

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**



(use as many sheets as necessary)

## **Complete if Known**



Application Number	09/779,086
Filing Date	February 7, 2001
First Named Inventor	Chinery, R., et al.
Group Art Unit	1639
Examiner Name	Bennett Celsa
Attorney Docket Number	04676.105058 ATH 108 CON 1

Sheet 2 of 10

## **U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	BA	5,783,596		MEDFORD, et al.	07-21-1998	
	BB	5,792,787		MEDFORD, et al.	08-11-1998	
	BC	5,807,884		MEDFORD, et al.	09-15-1998	
	BD	5,811,449		MEDFORD, et al.	09-22-1998	
	BE	5,821,260		MEDFORD, et al.	10-13-1998	
	BF	5,846,959		MEDFORD, et al.	12-08-1998	
	BG	5,877,203		MEDFORD, et al.	03-02-1999	
	BH	6,121,319		SOMERS	09-19-2000	
	BI	6,147,250		SOMERS	11-14-2000	
	BJ	6,448,019	B1	MENDELSON, et al.	09-10-2002	
	BK	6,548,699	B1	SOMERS	04-15-2003	
	BL	6,602,914	B2	MENG	04-05-2003	

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
	BM	DE	DT 27 16 125	A1	KOBAYAKAWA, et al.	10-27-1977		
	BN	EP	0,292,660	A2	KU, et al.	11-30-1988		
	BO	EP	0,348,203	A1	KITA, et al.	02-24-1993		
	BP	EP	0,405,788	A2	MATSUMOTO, et al.	01-11-1995		
	BQ	EP	0,418,648	B1	JENDRALLA, et al.	03-27-1991		
	BR	EP	0,621,255	A1	REGNIER, et al.	10-26-1994		

Examiner  
Signature



Date  
Considered

5/15/01


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.



PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0551-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number **09/779,086**  
Filing Date **February 7, 2001**  
First Named Inventor **Chinery, R., et al.**  
Group Art Unit **1639**  
Examiner Name **Bennett Celsa**  
Attorney Docket Number **04676.105058 ATH 108 CON 1**

Sheet **3** of **10**

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
<i>[initials]</i>	CA	EP	0,763,527	B1	REGNIER, et al.	04-26-2000		
	CB	FR	2,130,975		ARIES	11-10-1972		
	CC	FR	2,133,024		ARIES	11-24-1972		
	CD	FR	2,134,810		ARIES	12-08-1972		
	CE	FR	2,140,769		ARIES	01-19-1973		
	CF	FR	2,140,771		ARIES	01-19-1973		
	CG	FR	2,168,137		DYNACHIM	01-17-1972		✓
	CH	GB	L 136,539		UNIROYAL	12-28-1968		
	CI	GB	L 199,871		CONSOLIDATION COAL	07-22-1970		
	CJ	JP	7-328425			12-17-1995		
	CK	JP	8040888 Abstract	A	AJINOMOTO	02-13-1996		
	CL	WO	93/20691	A1	TYKOCINSKI, et al.	10-28-1993		
	CM	WO	94/20113 A1	A1	DARLINGTON, et al.	09-15-1994		
	CN	WO	95/09365	A1	SCHLESSING, et al.	04-06-1995		
	CO	WO	95/15760	A1	MAO, et al.	06-15-1995		
	CP	WO	95/26719	A1	SHARPE, et al.	10-12-1995		
	CQ	WO	95/30415	A1	MEDFORD, et al.	11-16-1995		
	CR	WO	96/16989	A1	HALAZONETIS, T.D.	06-06-1996		
	CS	WO	97/15546	A1	AOKI, et al.	05-01-1997		
	CT	WO	98/51289	A2/A3	MEDFORD, et al.	11-19-1998		
<i>[initials]</i>	CU	WO	98/51662	A2/A3	MEDFORD, et al.	11-19-1998		

Examiner  
Signature

*[Signature]*

Date  
Considered

*5/15/04*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Issue date of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

## **Complete If Known**

Application Number	09/779,086
Filing Date	February 7, 2001
First Named Inventor	Chinery, R., et al.
Group Art Unit	1639
Examiner Name	Bennett Celsa
Attorney Docket Number	04676.105058 ATH 108 CON 1

Sheet 4 of 10

## **OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
M	DA	Advanced Cancer Meta-Analysis Project (P. Piedbois, <i>et al.</i> ), "Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate", <i>J. Clin. Oncol.</i> , 10(6):896-903 (June, 1992).	
	DB	AKIRA, S., <i>et al.</i> , "A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family", <i>EMBO J.</i> , 9(6):1897-1906 (1990).	
	DC	AKIRA, S., <i>et al.</i> , "IL-6 and NF-IL6 in acute phase response to viral infection", <i>Immunol. Rev.</i> , 127:25-50 (1992).	
	DD	ANDERSON, T.J., <i>et al.</i> , "The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion", <i>N. Eng. J. Med.</i> , 332(8):488-493 (1995).	
	DE	ANONYMOUS, "AtheroGenics announces positive Phase II results from CART-1 clinical trial for restenosis: study analyses suggest AGI-1067 directly affects coronary artery disease", <i>Atherogenics, Inc., Press Release</i> , (2001).	
	DF	BARNHART, J.W., <i>et al.</i> , "Chapter 10: The Synthesis, metabolism, and biological activity of probucol and its analogs, 277-299 XP002095165	
	DG	BARON, J.L., <i>et al.</i> , "The pathogenesis of adoptive murine autoimmune diabetes requires an interaction between $\alpha$ -4-integrins and vascular cell adhesion molecule-1", <i>J. Clin. Invest.</i> 93:1700-1708 (April 1994).	
	DH	BERKOWITZ, D.B., <i>et al.</i> , "Synthesis of the ( $\alpha$ , $\alpha$ -difluoroalkyl)phosphonate analogue of phosphoserine", <i>Tet. Lett.</i> , 35(35):6445-6448 (July 1994)	
	DI	BOWRY, V.W., <i>et al.</i> , "Vitamin E in human low-density lipoprotein: when and how this antioxidant becomes a pro-oxidant", <i>Biochem. J.</i> 288:341-344 (1992).	
	DJ	BROWN, <i>et al.</i> , "Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis", <i>Ann. Rev. Biochem.</i> , 52:223-261 (1983).	
	DK	BURKLY, L.C., <i>et al.</i> , "Protection against adoptive transfer of autoimmune diabetes mediated through very late antigen-4 integrin", <i>Diabetes</i> , 43:529-534 (April 1994).	
	DL	CAMPBELL, A. <i>et al.</i> , "Reticulum cell sarcoma: two complete "spontaneous" regressions, in response to high-dose ascorbic acid therapy", <i>Oncology</i> , 48(6):495-497 (1991). XP002074537	
	DM	CAO, <i>et al.</i> , "Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells", <i>Genes &amp; Dev.</i> , 5:1538-1552 (1991).	
M	DN	CAREW, <i>et al.</i> , "Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants <i>in vivo</i> can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 84:7725-7729 (November 1987).	

Examiner Signature		Date Considered	5/15/06
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/779,086
Filing Date	February 7, 2001
First Named Inventor	Chinery, R., et al.
Group Art Unit	1639
Examiner Name	Bennett Celsa
Attorney Docket Number	04676.105058 ATH 108 CON 1

Sheet 5 of 10

## **OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
MC	EA	CHANG, et al., "Molecular cloning of a transcription factor, AGP/EBP, that belongs to members of the C/EBP family", <i>Mol. Cell. Biol.</i> , 10(12):6642-6653 (December 1990).	
	EB	CHINERY, R., et al., "Antioxidant-induced nuclear translocation of CCAAT/enhancer-binding protein beta. A critical role for protein kinase A-mediated phosphorylation of Ser <sup>299</sup> ", <i>J. Biol. Chem.</i> , 272(48):30356-30361 (11/28/1997). Erratum: <i>J. Biol. Chem.</i> , 273:15308 (1998).	
	EC	CHINERY, R., et al., "Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21 <sup>WAF1/CIP1</sup> via C/EPB $\beta$ ", <i>Nat. Med.</i> , 3(11):1233-1241 (November 1997).	
	ED	COFFEY, R.J., Jr., et al., "Transforming growth factor $\alpha$ and $\beta$ expression in human colon cancer lines: Implications for an autocrine model", <i>Cancer Res.</i> 47:4590-4594 (September 1, 1987).	
	EE	COHEN, B., et al., "Prognosis of node-positive colon cancer", <i>Cancer</i> (Phila.), 67:1859-1861 (1991).	
	EF	COMINACINI, L., et al., "Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule 1 induced by oxidized LDL on human umbilical vein endothelial cells", <i>Free Radical Biol. Adhesion Med.</i> 22(1/2):117-127 (1997). XP002095164	
	EG	CROOK, et al., "p53 Point mutation in HPV neative human cervical carcinoma cell lines", <i>Oncogene</i> , 6:873-875 (1991).	
	EH	DeMEGLIO, P., et al., "Nuovi derivati del clopirato e del probucol. Studio preliminare dell'attivit� ipolipemizzante", <i>Farmaco, Ed. Sci.</i> , 40(11):833-844 (1985) (in Italian); "New derivatives of clofibrate and probucol. Preliminary studies on hypolipemic activity" <i>Chem. Abstracts</i> 104:28675 XP-002124424	✓
	EI	EL-DEIRY, W., et al., "WAF1, a potential mediator of p53 tumor suppression", <i>Cell</i> , 75:817-825 (November 19, 1993).	
	EJ	FARISS, M.W., et al., "The selective aniproliferative effects of $\alpha$ -tocopheryl hemisuccinate and cholesteryl hemisuccinate on murine leukemia cells result from the action of the intact compounds", <i>Cancer Res.</i> , 54(13):3346-3351 (July 1, 1994).	
	EK	FAURE, H., et al., "5-Hydroxymethyluracil excretion, plasma TBARS and plasma antioxidant vitamins in Adriamycin-treated patients", <i>Free Radical Biol. &amp; Med.</i> , 20(7):979-983 (1996).	
	EL	FAVRE, B., et al., "The catalytic subunit of protein phosphatase 2A is carboxyl-methylated in vivo", <i>J. of Biol. Chem.</i> , 269(23):16311-16317 (1994). XP002090665	
	EM	FEARON, E.R., et al., "Progressing toward a molecular description of colorectal cancer development", <i>FASEB J.</i> , 6:2783-2790 (July 1992).	
MC	EN	FOLKMAN, J., et al., "Angiogenesis", <i>J. Biol. Chem.</i> , 267(16):10931-10934 (June 5, 1992).	

Examiner Signature

Date Considered


5/15/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

## **Complete if Known**

Application Number	09/779,086
Filing Date	February 7, 2001
First Named Inventor	Chinery, R., et al.
Group Art Unit	1639
Examiner Name	Bennett Celsa
Attorney Docket Number	04676.105058 ATH 108 CON 1

Sheet	6	of	10
-------	---	----	----

## **OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>8</sup>
AC	FA	FRUEBIS, J.A., et al., "A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits", <i>J. Clinical Investigation</i> , Inc., 94:392-398 (July 1994).	
	FB	GEETHA, A., et al., "Levels of serum antioxidants in doxorubicin-treated rats - influence of vitamins E and C", <i>Curr. Sci.</i> , 58(19):1100-1102 (October 5, 1989). <i>Chem. Abstr.</i> 112:69504 (1990).	
	FC	GERSHBEIN, L.L., et al., "Action of drugs and chemical agents on rat liver regeneration", <i>Drug and Chemical Toxicology</i> , 8(3) 125-143 (1985).	
	FD	GUO, H.B., et al., "Clinical significance of serum S100 in metastatic malignant melanoma", <i>Eur. J. Cancer</i> , 31A(6):924-928 (1995).	
	FE	HAAS, A.L., et al., "Vitamin E inhibits proliferation of human Tenon's capsule fibroblasts in vitro", <i>Ophthalmic Res.</i> , 28(3):171-175 (1996). <i>Chem. Abstr.</i> 125:158572 (1996).	
	FF	HACKER, M.P., et al., "Effect of disulfiram (tetraethylthiuram disulfide) and diethyldithiocarbamate on the bladder toxicity and antitumor activity of cyclophosphamide in mice", <i>Cancer Res.</i> , 42(11):4490-4494 (November 1982).	
	FG	HEEG, et al., "Plasma levels of Probucol in man after single and repeated oral doses", <i>La Nouvelle Presse Medicale</i> , 9(40):2990-2994 (October 30, 1980). <i>Abstract in English</i> .	
	FH	HENDRICKS-TAYLOR, L.R., et al., "The CCAAT/Enhancer Binding Protein (C/EBPα) gene (CEBPA) maps to human chromosome 19q13.1 and the related nuclear factor NF-IL6 (C/EBPβ) gene (CEBPB) maps to human chromosome 20q13.1", <i>Genomics</i> , 14(1):12-17 (Jan. 1992).	
	FI	IADEMARCO, M.F., et al., "Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1)", <i>J. Biol. Chem.</i> 267(23):16323-16329 (August 15, 1992).	
	FJ	KAPILOFF, M.S., et al., "Variable effects of phosphorylation of Pit-1 dictated by the DNA response elements", <i>Science</i> , 253:786-789 (August 16, 1991).	
	FK	KHINE, M.B.B.S., et al., "High frequency of allelic deletion on chromosome 17p in advanced colorectal cancer", <i>Cancer (Phila.)</i> , 73(1):28-35 (January 1, 1994).	
	FL	KOCH, A.E., et al., "Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues", <i>Lab. Invest.</i> , 64(3):313-320 (1991).	
	FM	KOVACH, J.S., et al., "Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 93:1093-1096 (February 1996).	
M	FN	KOWENS-LEUTZ, B., et al., "Novel mechanism of C/EPBbeta (NF-M) transcriptional control: activation through depression", <i>Genes and Development</i> , 8:2781-2791 (1984). XP002090664	

Examiner Signature

*[Handwritten Signature]*

Date Considered

5/15/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **7** of **10**

### Complete If Known

Application Number	09/779,086
Filing Date	February 7, 2001
First Named Inventor	Chinery, R., et al.
Group Art Unit	1639
Examiner Name	Bennett Celsa
Attorney Docket Number	04676.105058 ATH 108 CON 1

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
ML	GA	KUNSCH, C., et al., "Oxidative stress as a regulator of gene expression in the vasculature", <i>Circ. Res.</i> 85:753-766 (1999).	
	GB	KUZUYA, M., et al., "Probucol prevents oxidative injury to endothelial cells", <i>J. Lipid Res.</i> , 32:197-204 (1991).	
	GC	LANDSCHULZ, et al., "Isolation of a recombinant copy of the gene encoding C/EBP gene", <i>Genes &amp; Dev.</i> , 2:786-800 (1988).	
	GD	LANKIN, V.A., et al., "Antiradical and antioxidative properties of probucol and its structural analog during oxidation of unsaturated phospholipids in natural and artificial membranes", <i>Chemical Abstracts</i> , 127(6):75973u (1996). [Original: <i>Dokl. Akad. Nauk</i> , 351(4):554-557 (1996) [in Russian]]	
	GE	Li, L., et al., Inst. Medicinal Biological Techn. China, "New water soluble dan phenolic acid A for treating cancer", CN 1,110,139 A; 18 October 1995; Abstract, WPI Derwent Publications Ltd., 97-373441 (1995). XP002080080.	
	GF	MAHONEY, C.W., et al., "Phosphorylation of CCAAT-enhancer binding protein by protein kinase C attenuates site-selective DNA binding", <i>J. Biol. Chem.</i> , 267(27):19396-19403 (September 25, 1992).	
	GG	MAO, et al., "Antioxidant activity of Probucol and its analogues in hypercholesterolemic Watanabe rabbits", <i>J. Med. Chem.</i> , 34(18) 298-302 (1991).	
	GH	MAO, et al., "Attenuation of atherosclerosis in a modified strain of hypercholesterolemic Watanabe rabbits with use of a Probucol analogue (MDL#29,311) that does not lower serum cholesterol", <i>Arteriosclerosis and Thrombosis</i> , 11(5):1266-1275 (September / October 1991).	
	GI	MARTIN-JIMENEZ, M., et al., "Failure of high dose tocopherol to prevent alopecia induced by doxorubicin", <i>N. England J. Medicine</i> (USA), 315(14):894-895 (10/02/1986). <i>Chem. Abstr.</i> 86:3386.	
	GJ	MEDVEDEV, A.I., et al., "Synthesis and properties of some new derivatives of 3,5-di-tert-butyl-4-hydroxythiophenol", <i>Chemical Abstracts</i> , 86:5066m (1977). [Original at <i>Tizisy Dokl. Nauchn. Sess. Khim. Tekhnol. Org. Soedin. Sery Semistykhn. Neftei</i> , 13 <sup>th</sup> , 23-4 (1974) [in Russian]].	
	GK	MENG, et al., "Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis", <i>Bioorg. &amp; Med. Chem. Lett.</i> 12:2545-2548 (2002).	
	GL	MILLER, G.J., "High density lipoproteins and atherosclerosis", <i>Ann. Rev. Med.</i> , 31:97-108 (1980).	
	GM	MORALES-DUCRET, J., et al., "α4β1 integrin (VLA-4) ligands in arthritis: vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes", <i>J. Immunol.</i> , 149(4):1424-1431 (August 15, 1992).	
ML	GN	NEUWORTH, M.B., et al., "Synthesis and hypocholesterolemic activity of alkylidenedithio bishenols", <i>J. Med. Chem.</i> , 13(4):722-725 (1970). XP-002124423	

Examiner  
Signature

Date  
Considered


5/15/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/779,086
		Filing Date	February 7, 2001
		First Named Inventor	Chinery, R., et al.
		Group Art Unit	1639
		Examiner Name	Bennett Celsa
		Attorney Docket Number	04676.105058 ATH 108 CON 1
Sheet	8	of	10

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
ML	HA	OBERLEY, L.W., et al., "Antitumor therapies based on inhibition of antioxidant enzymes", Oxy Radicals Their Scavenger Syst., Proc. Int. Conf. Superoxide Superoxide Dismutase, 3rd (1983), Meeting Date 1982, Vol. 2:242-254. Editor(s): Cohen, G., and Greenwald, R.A. Publisher: Elsevier, New York, NY. Chem. Abstr. 100:326 (1984).	
	HB	OFFERMAN, M.K., et al., "Antioxidant sensitive regulation of inflammatory response genes in Kaposi's sarcoma cells", J. of AIDS and Hum. Retro., 13(1):1-11 (1996). XP002089729	
	HC	OHKAWARA, Y., et al., "In situ expression of the cell adhesion molecules in bronchial tissues from asthmatics with air flow limitation: In vivo evidence of VCAM-1/VLA-4 interaction in selective eosinophil infiltration", Am. J. Respir. Cell. Mol. Biol., 12:4-12 (1995).	
	HD	OROSZ, C.G., et al., "Role of the endothelial adhesion molecule VCAM in murine cardiac allograft rejection", Immunol. Lett., 32:7-12 (1992).	
	HE	PARTHASARATHY, S., et al., "Probucol inhibits oxidative modification of low density lipoprotein", J. Clin. Invest., 77:641-644 (1986).	
	HF	PATTON, J.G., et al., "Monoclonal antibodies to human plasma low-density lipoproteins. II. Evaluation for use in radioimmunoassay for apolipoprotein B in patients with coronary artery disease", Clin. Chem., 29(11):1898-1903 (1983).	
	HG	PILEWSKI, J.M., et al., "Cell adhesion molecules in asthma: homing, activation, and airway remodeling", J. Respir. Cell. Mol. Biol., 12:1-3 (1995).	
	HH	POLI, V., et al., "IL-6DBP, a nuclear protein involved in Interleukin-6 signal transduction, defines a new family of leucine zipper proteins related to C/EBP", Cell, 63:643-653 (November 2, 1990).	
	HI	PRASAD, K.N., et al., "Vitamin E increases the growth inhibitory and differentiating effects of tumor therapeutic agents on neuroblastoma and glioma cells in culture 40840", Proceedings of the Society for Experimental Biology and Medicine, 164(2):158-163 (1980); Biological Abstracts, 70:70052454. XP002080077.	
	HJ	PRITCHARD, D.M., et al., "Apoptosis and gastrointestinal pharmacology", Pharmacol. Ther., 72(12):149-169 (1996).	
	HK	RABB, H.A., et al., "The role of the leukocyte adhesion molecules VLA-4, LFA-1 and Mac-1 in allergic airway responses in the rat", Am. J. Respir. Crit. Care Med., 149:1186-1191 (1994).	
ML	HL	RAMASAMY, S., et al., "Modulation of expression of endothelial nitric oxide synthase by nordihydrogualeic acid, a phenolic antioxidant in cultured endothelial cells", Molecular Pharmacology, 56:116-123 (1999); available online at http://www.molpharm.org	


Examiner Signature		Date Considered	5/15/01
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → 

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT



(use as many sheets as necessary)

### Complete If Known

Application Number	09/779,086
Filing Date	February 7, 2001
First Named Inventor	Chinery, R., et al.
Group Art Unit	1639
Examiner Name	Bennett Celsa
Attorney Docket Number	04676.105058 ATH 108 CON 1

Sheet 9 of 10

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	IA	RIGHETTI, S.C., et al., "A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma", <i>Cancer Res.</i> , 56:689-693 (Feb. 15, 1996).	
	IB	RINNINGER, et al., "ProbucoI enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism", <i>Atheroscler. Throm. Vasc. Biol.</i> , 19:1325-1332 (1999). XP-008001008.	
	IC	RIORDAN, H.D., et al., "Case study: high dose intravenous Vitamin C in the treatment of a patient with adenocarcinoma of the kidney", <i>J. Orthomolecular Med.</i> , 5(1) 5-7 (1990). XP002074538	
	ID	RIPOLL, E.A.P., et al., "Vitamin E enhances the chemotherapeutic effects of Adriamycin on human prostatic carcinoma cells in vitro", <i>J. Urol.</i> , 136(2):529-531 (1986). <i>Biological Abstracts</i> , 82:82084938. XP002080075	
	IE	ROBERTS, C.P., et al., "Regulation of monocyte to macrophage differentiation by antigluco corticoids and antioxidants", <i>Am. J. Obstet. Gynecol.</i> , 179(2):354-362 (1998).	
	IF	RÖSL, F., et al., "Differential regulation of the JE gene encoding the monocyte chemoattractant protein (MCP-1) in cervical carcinoma cells and derived hybrids", <i>J. Virology</i> , 68(4):2142-2150 (1994) <i>Biological Abstracts</i> 94:97193049. XP002089733	
	IG	RYDEN, T.A., et al., "Avian retroviral long terminal repeats bind CCAAT/ Enhancer-Binding Protein", <i>Mol. Cell. Biol.</i> , 9(3):1155-1164 (1989).	
	IH	SAWAYAMA, Y., et al., "Effects of ProbucoI and Pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia", <i>Journal of the American College of Cardiology</i> , 39(4):610-616 (2002)	
	II	SCHEFFNER, M., et al., "The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 88:5523-5527 (1991).	
	IJ	SINGH, S.V., et al., "Cytochrome P450 reductase, antioxidant enzymes and cellular resistance to doxorubicin", <i>Biochem. Pharmacol.</i> , 40(2):385-387 (1990). <i>Chem. Abstr.</i> 113:108901 (1990).	
	IK	STEINBERG, D., et al., "Modifications of low-density lipoprotein that increase its atherogenicity", <i>N. Eng. J. Med.</i> , 220(14):915-924 (1989).	
	IL	SUBRAMANIAN, S., et al., "Oxidant and antioxidant levels in the erythrocytes of breast cancer patients treated with CMF", <i>Med. Sci. Res.</i> , 21(2):79-80 (1993). <i>Chem. Abstr.</i> 118:161022 (1993).	
	IM	SZCZEPANSKA, I., et al., "Inhibition of leucocyte migration by cancer chemotherapeutic agents and its preventions by free radical scavengers and thiols", <i>Eur. J. Haematology</i> , 40(1):69-74 (1988); <i>Biological Abstracts</i> 85:85106445. XP002080076	

Examiner  
Signature

Date  
Considered


5/15/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

## **Complete If Known**

Application Number	09/779,086
Filing Date	February 7, 2001
First Named Inventor	Chinery, R., et al.
Group Art Unit	1639
Examiner Name	Bennett Celsa
Attorney Docket Number	04676.105058 ATH 108 CON 1

Sheet 10 of 10

## **OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MC	JA	TARDIF, J.C., et al., "Antioxidants and restenosis: human studies", in Tardif, J.C., et al., eds., Antioxidants and Cardiovascular Disease, Boston, Mass.: Kluwer Academic Publishers (2000):175-191.	
	JB	TARDIF, J.C., et al., "Effects of AGI-1067 and Probucol after percutaneous coronary interventions", <i>Circulation</i> , 107(4):552-558 (2003).	
	JC	TRAUTWEIN, C., et al., "Protein kinase A and C site-specific phosphorylations of LAP (nf-IL6) modulate its binding affinity to DNA recognition elements", <i>J. of Clin. Investig.</i> , 93(6):2554-2561 (1994). XP002090666	
	JD	TYAGI, S.C., et al., "Reduction-oxidation (redox) state regulation of extracellular matrix metalloproteinases and tissue inhibitors in cardiac normal and transformed fibroblast cells", <i>J. Cellular Biology</i> , 61(1):139-151 (1996): abstract from <i>Biological Abstracts</i> , 96:98730849. XP002089732	
	JE	WEITZMAN, S.A. et al., "Prospective study of tocopherol prophylaxis for anthracycline cardiac toxicity", <i>Curr. Ther. Res. Cl</i> , 28(5):682-686 (11/1980). <i>Chem. Abstr.</i> 80:3993.	
	JF	WHITTAKER, J.A., et al., "Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukemia", <i>British Medical Journal</i> (England), 288:283-284 (01/28/1984). <i>Chem. Abstr.</i> 84:2926.	
	JG	WILLIAMS, et al., "A family of C/EBP-related proteins capable of forming covalently linked leucine zipper dimers in vitro", <i>Genes &amp; Development</i> , 5:1553-1567 (1991).	
	JH	YANG, X.-D., et al., "Inhibition of insulinitis and prevention of diabetes in nonobese diabetic mice by blocking L-selectin and very late antigen 4 adhesion receptors", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 90:10494-10498 (1993).	

3273118\_5

Examiner Signature		Date Considered	5/15/06
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.